Category: Stock Market

  • Alibaba Drops After Projecting Slowing Growth in Uncertain Times

    Alibaba Drops After Projecting Slowing Growth in Uncertain Times(Bloomberg) — Alibaba Group Holding Ltd. slid after projecting revenue growth will slow this year, reflecting post-Covid 19 economic uncertainty at home as well as the potential for U.S.-Chinese tensions to disrupt its business.Its stock slid as much as 4% in Hong Kong Monday, after a drop of almost 6% in New York before the weekend. The e-commerce giant forecast sales growth this year of at least 27.5% to more than 650 billion yuan ($91 billion), down from 35% previously and slightly below analysts’ estimates. While it posted a better-than-expected 22% rise in March quarter revenue of 114.3 billion yuan, that marked its slowest pace of expansion on record.Online shopping began to bounce back from March, executives said Friday. But the tepid outlook demonstrates the world’s second-largest economy has yet to fully shake off Covid-19, with consumers still hesitant about spending on big-ticket items. Asia’s most valuable corporation is tackling also the rise of rivals such as ByteDance Ltd. and Pinduoduo Inc. And the Tmall operator is going head-to-head with Tencent Holdings Ltd. for internet leadership in everything from online media to payments and cloud computing. JD.com Inc., the No. 2 Chinese online retailer, forecast better-than-expected revenue this quarter.“The market is a bit disappointed despite the strength given 2Q guidance of 20-30% YoY growth for JD and 99% GMV growth in 1Q20 for PDD,” CICC analyst Natalie Wu wrote. “We regard Alibaba’s advantage as a market leader as intact and unchanged in the longer run, though it may take several quarters for market sentiment to swing back.”Read more: Alibaba Sales Growth Plumbs New Lows While Uncertainty EscalatesAlibaba has lost more than $70 billion of market value since the coronavirus first erupted in January, and now has to grapple with not just an uncertain global economic environment but also any potential fallout from U.S.-Chinese financial tensions. On Friday, executives sought to assuage concerns about a U.S. bill that mandates much closer accounting scrutiny of U.S.-listed Chinese companies and may bar them from American bourses.Chief Financial Officer Maggie Wu said Friday Alibaba’s financial statements have been consistently prepared in accordance with U.S. GAAP accounting measures and were beyond reproach. “The integrity of Alibaba’s financial statements speak for itself, we have been an SEC filer since 2014 and hold ourselves to the highest standard,” she told analysts on a conference call. “We will endeavor to comply with any legislation whose aim is to protect and bring transparency to investors who buy securities on U.S. stock exchanges.”The bigger short-term challenge is in reviving growth: Alibaba’s bread-and-butter customer management or marketing business grew just 3% in the March quarter. Much of that stems from weaker consumer sentiment during the coronavirus-stricken quarter, when total Chinese e-commerce rose just 5.9% or at less than a third of 2019’s pace, according to government data. Jefferies analysts led by Thomas Chong wrote that Alibaba’s guidance was in fact a positive when viewed against an array of uncertainties gripping the post-Covid 19 global economic environment.What Bloomberg Intelligence SaysUser engagement and transaction volume have rebounded in April and May to precrisis levels, which bodes well for normalized sales growth ahead, especially as merchant-support measures are gradually rolled back.\- Vey-Sern Ling and Tiffany Tam, analystsClick here for the research.Rival PDD posted a revenue rise of 44% on Friday, down sharply from 91% in the previous quarter but ahead of expectations. Its sales and marketing expenses jumped 49%. PDD’s shares climbed 15% Friday.Alibaba’s March-quarter net income was 3.2 billion yuan, down 88% from a year ago when it booked an 18.7 billion yuan one-time gain on investments. In February, Alibaba declared a waiver of some service fees for merchants struggling financially during the outbreak on its main direct-to-consumer Tmall platform. In April, the company rolled out a new 10-billion-yuan subsidy program for Tmall users to buy electronics, encroaching on JD.com’s traditional turf. These initiatives may further compress margins for the June quarter.“The challenging part is for them to achieve the same amount of growth this year,” said Steven Zhu, a Shanghai-based analyst with Pacific Epoch. “Just because they are too big, for the same amount of growth, they need to spend much more effort.”But executives were confident in a gradual e-commerce recovery over the year. Beyond its main business, younger divisions such as its cloud computing arm should buoy the bottom line. That division’s revenue jumped 58% in the quarter.“Despite a challenging quarter due to reduced economic activities in light of the COVID-19 pandemic in China, we achieved our annual revenue guidance,” Wu said in a statement. “Although the pandemic negatively impacted most of our domestic core commerce businesses starting in late January, we have seen a steady recovery since March.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/2A2eqLU

  • Hong Kong Protesters Clash With Police After China Tightens Grip

    Hong Kong Protesters Clash With Police After China Tightens GripMay.24 — Hong Kong protesters battled with riot police in busy downtown areas on Sunday, showing their opposition toward China’s dramatic move to crack down on dissent in the biggest demonstration since the coronavirus swept through the city in January. Stephen Engle reports on “Bloomberg Daybreak: Australia.”

    from Yahoo Finance https://ift.tt/2LWLSWU

  • Apple China Sales On Recovery Path In April, iPhone Sales Jump 160% – Report

    Apple China Sales On Recovery Path In April, iPhone Sales Jump 160% – ReportApple Inc.’s (AAPL) China sales continued to recover in April, driven partly by the launch of a cheaper iPhone, CNBC reported.The tech giant sold 3.9 million iPhones in China in April, reflecting a 160% surge from March figures, when it sold 1.5 million smartphones, the Shanghai-based market research firm CINNO Research told CNBC.The signs of a recovery path since February comes as the world’s second largest economy slowly reopens again after the coronavirus pandemic forced store closures earlier this year that led to sales declines. China iPhone sales slumped 60% in February year-on-year. Since mid-March, all stores in China have reopened.Apple, which launched its second-generation iPhone SE in mid-April, started to sell the device in China later that month. It starts at 3,299 yuan ($464) in the mainland. iPhone SE accounted for 24% of all of Apple’s 3.9 million iPhone sales in April, according to CINNO Research.In April, overall smartphone shipments in China rose over 94% to 40.8 million compared with the previous month, according to state-backed think tank, China Academy of Information and Communications Technology.Five-star analyst Daniel Ives at Wedbush, who has a Buy rating on the stock with a $350 price target, sees a seminal moment for Apple in China with pressure on both ends of the spectrum from a supply and demand perspective amid renewed tensions between the U.S. and China.The recent Department of Commerce ban on Huawei, preventing it from purchasing semiconductors from U.S. companies, has ignited fears of retaliatory moves against companies such as Apple.“On the demand story, a relative bright spot during this COVID-19 Category 5 storm remains China which represents a growth linchpin region for the company representing roughly 20% of all iPhone upgrades over the next 12 to 18 months with our estimation that 60 million to 70 million iPhones in China are currently in the window of opportunity,” Ives wrote in a note to investors. “From a supply chain perspective we believe Apple would only be able to move 5%-7% of iPhone production to India/ Vietnam over the 18 to 24 months if the China situation/tensions spirals down a more negative and nasty path over the coming months.”Ives believes though that “while uncertainty will add to an already worrisome near-term situation around the global demand picture for Apple, the fundamental impact on iPhone production and the potential backlash in the region thus far is more bark than bite”.Turning now to the rest of Wall Street, analysts have a bullish outlook on Apple’s stock. The Strong Buy consensus is backed up by 27 Buys with the rest split between 4 Holds and 1 Sell. The $318.93 average price target indicates shares are fully priced (See Apple stock analysis on TipRanks).Related News: Apple To Reopen More Than 25 U.S. Stores This Week Google, Apple Roll Out Coronavirus Contact Tracing Technology Apple is Said to Snap Up Startup NextVR For Virtual Reality Content; Top Analyst Sees Buying Opportunity More recent articles from Smarter Analyst: * Vermilion Energy CEO Steps Down With Immediate Effect * American Airlines and Others Given Go-Ahead to Reduce Route Coverage * Facebook Workplace Hits 5 Million Paid Users As Remote Work Demand Rises * NYSE to Reopen Its Trading Floor on Tuesday

    from Yahoo Finance https://ift.tt/2LY5Os8

  • BlackRock Investment Institute Is ‘Underweight’ Japan Stocks

    BlackRock Investment Institute Is 'Underweight' Japan StocksMay.25 — Ben Powell, chief APAC investment strategist, at BlackRock Investment Institute, shares his views on the region’s markets and global policies. He speaks with Haslinda Amin and Tom Mackenzie on “Bloomberg Markets: Asia.”

    from Yahoo Finance https://ift.tt/2ARb7ay

  • Bayer says it makes progress in settlement talks over weedkiller

    Bayer says it makes progress in settlement talks over weedkillerBayer said on Monday it had made progress seeking a settlement over claims its glyphosate-based Roundup weedkiller causes cancer, after Bloomberg reported the company reached a verbal agreement on about 50,000 to 85,000 cases. In April, Bayer’s management regained shareholder support for its handling of the litigation process. Bloomberg cited people familiar with the negotiations as saying that the deals have yet to be signed and Bayer is likely to announce the settlements in June.

    from Yahoo Finance https://ift.tt/2TBPku7

  • 3 exciting small cap ASX healthcare shares to watch

    asx healthcare shares

    Due to new technologies and favourable industry tailwinds, I think there are a number of small cap ASX healthcare shares which have the potential to grow materially over the next 10 years.

    Three small cap healthcare shares to add to your watchlist right now are listed below. Here’s why I think they are worth watching:

    Alcidion Group Ltd (ASX: ALC)

    The first small cap ASX healthcare share to watch is Alcidion. It is a health informatics company aiming to transform healthcare with smart, intuitive technology solutions. The company has a growing portfolio of software products and services that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. At present its software is in 215 hospitals, 42 healthcare organisations, and on 30,000 beds. I expect this to increase strongly in the coming years and drive strong sales growth.

    Medadvisor Ltd (ASX: MDR)

    Another ASX healthcare share to watch is Medadvisor. It is a growing software systems developer with a focus on addressing gaps in personal medication adherence. The company provides software that connects to pharmacy dispensing systems to automatically retrieve medication records. It also comes with an intelligent training, information, and reminder system to ensure correct and reliable medication use. In addition to this, the company is rolling out a medicine delivery service and a telehealth solution. The latter looks set to benefit from the rapid adoption of telehealth technology following the pandemic.

    Volpara Health Technologies Ltd (ASX: VHT)

    Another small cap ASX healthcare share which I believe has significant potential is Volpara. Its software leverages artificial intelligence imaging algorithms to assist with the early detection of breast cancer. It has been growing its market share in North America at an exceptionally strong rate. This led to the company recently reporting a 172% increase in annual recurring revenue (ARR) to NZ$18 million. The good news is that this is still only scratching at the surface of an estimated US$750 million ARR opportunity in breast cancer screening.

    And here are more top shares which analysts have just given buy ratings to. All five recommendations below look dirt cheap after the crash…

    5 cheap stocks that could be the biggest winners of the stock market crash

    Investing expert Scott Phillips has just named what he believes are the 5 cheapest and best stocks to buy right now.

    Courtesy of the crashing stock market, these 5 companies are suddenly trading at significant discounts to their recent highs… creating what could be incredible opportunities for bargain-hungry investors.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares to buy now… before the next stock market rally.

    See the 5 stocks

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Alcidion Group Ltd and MedAdvisor. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended Alcidion Group Ltd and MedAdvisor. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 exciting small cap ASX healthcare shares to watch appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2ziOaNl

  • CSL shares have underperformed the ASX 200 over the past month. What’s going on?

    Man asking financial questions

    The CSL Limited (ASX: CSL) share price has done the unthinkable and actually underperformed the broader S&P/ASX 200 Index (ASX: XJO) over the past month.

    To be frank, CSL shares normally beat the pants off the market. It managed to do this both in the 2016–2020 bull market and in the short-but-sharp bear market we saw in February and March of this year.

    But since mid-April, CSL shares have actually fallen around 10%, whilst the ASX 200 has rallied around 7% over the same period.

    What’s going on?

    Has CSL lost its magic?

    Well, in my opinion, the recent underperformance of CSL shares has nothing to do with the company itself. CSL hasn’t yet told the markets if it expects any material hit to revenue or earnings as a result of the coronavirus pandemic (apart from disruption to plasma collections). CSL isn’t actively joining the race for a COVID-19 vaccine, but (as Fool contributor Nikhil Gangaram pointed out today) the company is working on antibody-based medicines that will allow patients to recover faster without the use of a ventilator.

    We do know that CSL has obtained additional capital (US$750 million at 2.68%) through the bond market recently, but again, this doesn’t indicate anything of significance for investors in my view.

    So no, I don’t think CSL has lost its magic.

    Instead, I view the pullback in the CSL share price as a sign that investors might have got a little ahead of themselves in April.

    CSL shares reached lows of $270.88 in March, but by 9 April, CSL was back to $329 a share, just below the all-time high of $342.75 that we saw in February.

    Given what’s going on in the global economy, it’s possible investors decided this run-up was a little optimistic, and that’s why we are seeing a more subdued CSL share price in recent weeks.

    Are CSL shares a buy today?

    Although I’ve long thought CSL is a top company, it’s also a little too highly priced for me to consider a buy today. Even on today’s share price of $298.27, the company is still asking a price-to-earnings (P/E) ratio of 44.28. That’s a fairly high number for the ASX’s largest company, and one I don’t think is entirely justified by CSL’s future growth prospects.

    I might be waiting a while, but CSL is still not in the buy zone for me, despite its resilience and quality as a business.

    Instead, I’m looking at these 5 shares! Check them out in the report below!

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading 40% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    YES! SEND ME THE FREE REPORT!

    More reading

    Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post CSL shares have underperformed the ASX 200 over the past month. What’s going on? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2WXg0aQ

  • 2 cheap ASX shares to buy today

    hand outstretched with two coins in palm

    There are some cheap ASX shares out there that are trading at great value in my opinion, partly due to the coronavirus.  

    With some shares it’s hard to decide if they’re trading cheaply or not because it’s hard to gauge how to price the current and future earnings. It’s much easier to see when a quality business is trading cheaply compared to their assets.

    Here are two cheap ASX shares to buy today:

    Brickworks Limited (ASX: BKW)

    Brickworks is one of Australia’s biggest building materials businesses. It produces a variety of products including bricks, paving, roofing, precast and so on. Everyone is expecting there to be a construction slowdown later this year because of the coronavirus economic impacts. The same can be said for Brickworks’ US operations.

    But when you factor in the value of Brickworks’ other assets, it makes the construction side look extremely cheap. Brickworks currently owns a large chunk of Washington H. Soul Pattinson and Co Ltd (ASX: SOL), these shares are currently valued at approximately $1.75 billion. It also has a 50% stake of an industrial property trust which is worth $710 million. The value of these two divisions together comes to around $2.45 billion, which compares to Brickworks’ current market cap of $2.05 billion.

    Wouldn’t you want to buy a great building products company operating in two major markets for less than $0? That’s why I think Brickworks is a cheap ASX share.

    Future Generation Global Invstmnt Co Ltd (ASX: FGG)

    This is a special listed investment company (LIC). It donates 1% of its net assets each year to youth mental health charities. The LIC doesn’t change any management fees or performance fees. Future Generation Global invests in the funds of Australian fund managers that invest in overseas shares.

    These fund managers are meant to be among the best in Australia. They include names like Magellan Financial Group Ltd (ASX: MFG) and Cooper Investors.

    The global LIC has been a solid performer over the past three years to 30 April 2020. Its gross investment performance of 10.6% per annum outperformed the MSCI AC World Index (AUD) by 1.3% per annum. Outperformance makes a cheap ASX share even more attractive. 

    I think Future Generation Global is a cheap ASX share because at the end of April 2020 its pre-tax net tangible assets (NTA) per share was $1.426 per share, which is a 20% discount to today’s share price of $1.145. You wouldn’t be able to get that kind of discount by investing with the fund managers yourself.

    Foolish takeaway

    I think both of these ASX shares look cheap to me. Once construction starts again I think the current Brickworks share price will look very cheap. Brickworks also comes with a grossed-up dividend yield of 6%. However, Future Generation Global does offer much more diversification with international exposure. I think both shares are great, cheap buys today.

    They’re not the only cheap shares out there in my opinion. I’d also love to buy these top shares:

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading 40% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    YES! SEND ME THE FREE REPORT!

    More reading

    Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Brickworks. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 2 cheap ASX shares to buy today appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3ehrCve

  • European Launch of Kylie Skin Boosts Coty Stock by 15%

    European Launch of Kylie Skin Boosts Coty Stock by 15%Shares of Coty (COTY) rose by 15% on Friday to $3.85, after the company announced that its Kylie Skin products are now available at Douglas, a beauty retailer with around 2,400 locations across Europe. The announcement boosted Coty's valuation by a full $300 million. Douglas will offer six different products from the Kylie Skin line, including the Foaming Face Wash, Walnut Face Scrub, Face Moisturizer, Eye Cream, Vanilla Milk Toner and Vitamin C Serum.“We have started to build a strong foundation to support our strategic partnership with Kylie Jenner. The launch of Kylie Skin in Europe is a next step as we accelerate the integration and build Kylie Jenner’s beauty businesses into a global powerhouse brand,” said Simona Cattaneo, President of Luxury Brands at Coty.Coty acquired a controlling stake in Kylie Jenner's cosmetics startup, Kylie Cosmetics, last November for $600 million. The deal increased the company's debt load, but at the time management indicated that it expected its return on invested capital to exceed the associated cost by 2023.The stock fell significantly two weeks ago when Coty reported subpar quarterly results, revealing stalling revenue growth and falling net income. The stock has suffered through a very difficult year on Wall Street; even with Friday's jump, shares are down over 70% in the last year.TipRanks data reveals a Hold consensus for Coty.  Yet with the dramatic decline COTY shares has experienced of late, the analyst price target for COTY still represents 57% upside at $5.89 per share over the coming 12 months. (See COTY stock analysis on TipRanks)."Difficult operating environment for COTY and unfortunately things will likely get worse before they get better" summed up RBC Capital's Nik Modi. However, the stock's lone bull added that he believes "management is making the right structural decisions (i.e. cost cutting, shifting decision making to be more local, partnership with KKR) to position the Company well for a post-COVID environment."As a result Modi lowered his FY'20 sales/EBIT estimates, but left his price target unchanged at $8 (113% upside potential).Related News: Beleaguered Hertz Sinks 36% In After-Market On Bankruptcy Protection Filing Facebook Invests An Eye-Watering $5.7B in India’s Jio Platforms Tesla Asks China to Build Model 3 Cars with LFP Batteries – Report More recent articles from Smarter Analyst: * Facebook Workplace Hits 5 Million Paid Users As Remote Work Demand Rises * NYSE to Reopen Its Trading Floor on Tuesday * Agilent Up 5% On Solid Revenue Beat, But Top Analysts Stay Cautious * Facebook-Backed Reliance Launches Powerful Online Grocery Service In India

    from Yahoo Finance https://ift.tt/3goew18

  • Coronavirus: How Chinese rivals are trying to take Zoom’s crown

    Coronavirus: How Chinese rivals are trying to take Zoom's crownThe coronavirus lockdown has fuelled the market for teleconferencing technology apps.

    from Yahoo Finance https://ift.tt/2ZAldHo